Loading…
Ken GriffinReduced
Citadel Advisors · Q2 2026
$186.94M
470.08K shares · 0.1% of portfolio
Intuitive Surgical Inc
Intuitive Surgical Inc (ISRG) is listed on NASDAQ and classified in Medical Instruments & Supplies, part of the Healthcare sector. It is headquartered in Sunnyvale, United States and has 17,021 employees. The company is worth $156.8B and trades at 53.7x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $10.06B in fiscal 2025, up 20.5% from the year before. Net income was $2.86B. The share price is 26.5% below its 52-week high of $603.88. 10 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Baillie Gifford (Baillie Gifford & Co), at $1B. In that quarter, 4 of them opened or added to the position and 5 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +31.6% over 5Y.
today you would have $1,181.57▲ +18.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 19 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $566.36 | $521.96 | $337.36 | $265.35 | $359.30 | $272.70 | $197.05 | $159.64 | $121.65 | $70.46 | $60.68 | $58.77 | $42.68 | $54.49 | $51.45 | $28.64 | $33.71 |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings growing 21.8% a year plus a 0.0% dividend yield. Growth capped at 25%.
Median P/E of 24.3 among peers in the sector.
Median P/E of 51.2 across this company’s own years on record.
Cash flow growing 15.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| DHRDanaher Corp | $229.75 | 38.7x | 3.0x | 0.70% | 8.19% | $161.51B |
| PFEPfizer Inc | $30.42 | 40.0x | 2.0x | 5.65% | 5.01% | $173.38B |
| NVONovo Nordisk A S | $39.43 | 9.6x | 5.3x | 4.57% | 59.81% | $174.01B |
| ABTAbbott Laboratories | $102.51 |
| $14.11 |
| $35.89 |
| P/E | 51.2x | 72.0x | 81.3x | 67.1x | 72.7x | 77.1x | 92.8x | 51.2x | 50.5x | 63.2x | 33.8x | 35.1x | 47.6x | 23.0x | 30.7x | 37.6x | 27.2x | 51.2x | 24.8x | 87.3x |
| P/S | 13.1x | 20.0x | 22.3x | 16.7x | 14.9x | 22.5x | 22.1x | 15.3x | 14.7x | 13.1x | 9.1x | 8.6x | 9.1x | 6.5x | 9.0x | 10.4x | 7.1x | 11.1x | 5.7x | 21.0x |
| P/B | 8.2x | 11.3x | 11.3x | 8.9x | 8.4x | 10.8x | 9.9x | 8.3x | 8.2x | 8.6x | 4.3x | 4.7x | 5.7x | 4.2x | 5.5x | 6.9x | 4.9x | 7.6x | 3.9x | 14.2x |
| EPS | $7.87 | $6.42 | $5.03 | $3.65 | $4.66 | $2.94 | $3.85 | $3.16 | $1.92 | $2.09 | $1.73 | $1.23 | $1.86 | $1.78 | $1.37 | $1.05 | $0.66 | $0.57 | $0.41 |
| Profit margin | 27.02% | 28.38% | 27.81% | 25.24% | 21.25% | 29.85% | 24.33% | 30.80% | 30.29% | 21.38% | 27.28% | 24.69% | 19.65% | 29.62% | 30.14% | 28.17% | 27.02% | 22.11% | 23.35% | 24.06% |
| ROE | 15.13% | 16.02% | 14.13% | 13.51% | 11.98% | 14.32% | 10.90% | 16.69% | 16.89% | 14.04% | 12.78% | 13.63% | 12.39% | 19.16% | 18.34% | 18.71% | 18.74% | 15.13% | 16.13% | 16.26% |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
6 methods answered, across 3 families.
Room for errors in the reported numbers.
-53.2% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 37.4x |
| 3.4x |
| 2.46% |
| — |
| $177.38B |
| VRTXVertex Pharmaceuticals Inc | $535.17 | 31.0x | 6.7x | 0.00% | 23.54% | $135.64B |
| BMYBristol Myers Squibb Co | $63.00 | 13.9x | 5.8x | 4.00% | 46.60% | $128.69B |
